PER 0.00% 8.1¢ percheron therapeutics limited

Ann: ATL1102 for Multiple Sclerosis Phase IIb trial Update, page-9

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 13,692 Posts.
    lightbulb Created with Sketch. 1458
    Sorry People.i made a mistake...AEI insist that Approval for DMD is end of Sept 2017.
    For some reason I thought" by Sept."
    The HREC meeting date is the 4/sept/ 2017.(Ethics ).since it's the last meeting before the end of Sept..Lets hope we get the green light then.

    THe fact that ANP is still continuing with the Non diluting fund application is a good sign that the Clinical hold re IND trial design can be modified to get the FDA clearance.Let's hope.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.1¢
Change
0.000(0.00%)
Mkt cap ! $83.97M
Open High Low Value Volume
8.0¢ 8.1¢ 8.0¢ $61.91K 766.3K

Buyers (Bids)

No. Vol. Price($)
4 549730 8.0¢
 

Sellers (Offers)

Price($) Vol. No.
8.1¢ 94626 1
View Market Depth
Last trade - 15.59pm 31/10/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.